Haiying Cheng, MD
Internal Medicine · Bronx, NYNPI 1689724965
Payments from drug & device makers
Across 510 payments — averaging $3366.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$617K
- Janssen Research & Development, LLC$195K
- AstraZeneca$191K
- Boehringer Ingelheim Pharma GmbH & Co.kg$162K
- Boehringer Ingelheim$136K
- F. Hoffmann-la Roche AG$99K
- plus $316K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 200 | $617,228 |
| Janssen Research & Development, LLC | 55 | $195,110 |
| AstraZeneca | 18 | $190,804 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 20 | $162,016 |
| Boehringer Ingelheim | 20 | $136,392 |
| F. Hoffmann-la Roche AG | 47 | $99,341 |
| Daiichi Sankyo Inc. | 23 | $73,677 |
| Array Biopharma Inc | 45 | $64,665 |
| Eisai Inc. | 15 | $48,177 |
| Astrazeneca UK Limited | 12 | $46,794 |
| Regeneron | 9 | $29,166 |
| Spectrum Pharmaceuticals Inc. | 8 | $20,388 |
| Bayer | 11 | $10,254 |
| Fosun Pharma USA Inc. | 4 | $4,538 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $3,802 |
| Janssen Scientific Affairs, LLC | 3 | $3,190 |
| G1 Therapeutics, Inc. | 3 | $3,032 |
| Catalyst Pharmaceuticals, Inc. | 2 | $2,372 |
| Genentech USA, Inc. | 5 | $2,315 |
| Novocure Inc. | 1 | $2,000 |
| Boehringer Ingelheim International GmbH | 1 | $1,446 |
| Medtronic | 1 | $41 |
| EMD Serono, Inc. | 1 | $16 |
| Mirati Therapeutics, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $11 |
How this compares
$1,716,791 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.